505 (b) (2) approvals in May 2025

There are three 505(b)(2) NDAs approved by the USFDA and one NDA that received tentative approval from the USFDA in May 2025. The details are as follows.


More details can also be found in the API and IP newsletter published by us. 


Comments

Popular posts from this blog

Gland Pharma is expected to secure 180-day exclusivity for Angiotensin II Acetate.

Medical Reimbursement System in the US, J-Code, and the Potential Impact on 505(b)(2) Applications with Recent Changes